

2025


Institutional Investors'
Conference



TWSE: 4142

Adimmune Corporation





Disclaimer

- Adimmune has not released any financial forecast. Business and financial information presented in this brief and during the Q&A session, should they concern business operation or industrial development, may differ materially from actual results. These discrepancies are due to such risks and uncertainties as market demand changes, price fluctuations, competitive behavior, global economic conditions, exchange rate fluctuations, supply chains etc., which are beyond Adimmune's control.
- The forward-looking statements contained in this brief are based on Adimmune's current expectations and speak only as of the date hereof. Adimmune assumes no obligation to update forward-looking statements as the result of new information or future events or developments.

Agenda Overview

A. Company Profile

B. Business Outlook

C. Q&A



國際之光 · 免疫先鋒

國光生物科技股份有限公司

The only influenza vaccine manufacturer in Asia with both

EMA & US FDA GMP certifications

Established since 1965 (60-year experience in vaccines)
Chairman **Chi-Shean Chan, M.D.**

Employees **524** (as of July 2025)

Total Area **38,831 square meters**

Products **Influenza Vaccine, Enterovirus 71 Vaccine, Tetanus Vaccine, Tuberculin**

Technology Partner



CDMO Service **SANOVI PASTEUR**



Shenzhen Hepalink Group



Agenda Overview

A. Company Profile

B. Business Outlook

C. Q&A

Business Outlook

(QIV in South Hemisphere)



- **Oct 2023: Submission**
- **Jun 2025: Official on-site inspection (passed)**
- **Q4 2026: Obtaining marketing authorization (estimated timeline)**
- **Q4 2026: Launch of commercial batch production**

Business Outlook

CDMO – Recombinant Protein Vaccine Drug Product (New Demand)



- **Oct 2024:** Customer confirmed addition of a second filling line to expand U.S. market supply
- **Dec 2024:** Initiation of dedicated equipment set procurement and process qualification design
- **Q2 2025:** Completion of process qualification batch production and submission for new line approval
- **Q1 2026:** Completion of audit and marketing authorization update
- **Q2 2026:** Commercial production (Adimmune's annual supply capacity expected to double)

Business Outlook

(CDMO – New Demand)



- **CDMO Services for Client's Next-Generation Product**
- **Q1 2025: Procurement of dedicated equipment set (completed)**
- **Q2 2025: Initiation of technology transfer (completed)**
- **Q4 2026: Completion of process qualification batch production for the U.S. and European markets (estimated)**

Business Outlook

CDMO – Biosimilar (Marketing Authorization and Commercial Production)



- Q2 2025: Commercial batch production for Asia
- Q2 2025: Commercial batch production for North America
- Q2 2025: Completion of EMA site inspection
- Q3 2025: Launch of commercial batch production
- Q4 2025: Launch of Phase II Process Scale-up for PFS

Fill/Finish CDMO

Business Outlook

EV71 Vaccine (Marketing Authorization and Commercial Production)



- Q1 2025: Macau marketing authorization submission
- Q3 2025: Vietnam marketing authorization submission (in partnership with the Vietnam's largest state-owned vaccine company)
- Q3 2025: Thailand marketing authorization submission (estimated)
- Cell Culture Process Scale-up: 50L → 200L → 1000L
- Estimated annual capacity: 1–10 million doses



Business Outlook

(Strategic Development & New Product Co-Development)



- **Ongoing Expansion of Influenza Vaccine Market Overseas**

- Southern Hemisphere**

- Middle East & South Asia**

- **Strategic Partnerships – New Product Co-Development & Technology Transfer**

- Herpes Zoster Vaccine: Korea**

- Emerging Respiratory Infectious Disease+ Influenza Bivalent Vaccine**

Business Outlook

(New Capacity Deployment)



- **New Production Line (Automated Aseptic Filling Line)**

- Annual capacity: Approx. 4 million doses

- Expected commercial production launch: Q2 2026

- **Anticipated Business Impact**

- Supports commercial-scale manufacturing of customized, small-batch, and high-value products

- Enables clinical trial supply production, offering one-stop service from clinical to large-scale commercial manufacturing

- Enhances the value of existing capacity and improves production scheduling flexibility



Business Growth: Phase II

Phase I Globalization Expansion Strategy

Phase II Acceleration

Phase II Growth


Unit : NT\$ 0.1 Billion

Obtained the market authorization for influenza vaccine in China

Adimmune began its globalization strategy in 2015 with the acquisition of marketing authorization for its influenza vaccine in China. Since then, the company has achieved significant growth in both Adimmune's products and CDMO services, expanding its footprint from Taiwan to major global markets, including the U.S., Europe, China, Northeast Asia, Southeast Asia, Central Asia, and Eastern Europe.

By 2023, Adimmune successfully completed Phase I of its global expansion strategy. The strong performance of its partners in international markets has further solidified and strengthened these strategic partnerships.

As Adimmune moves into Phase II of its business growth, the company is building on the successful foundation established during Phase I of its global expansion and aims to drive further growth in its CDMO business, expand its own product portfolio into the southern hemisphere market, and introduce its bioreactor-derived Enterovirus 71 vaccine to the ASEAN region.





Q & A





THANK YOU

OFFICE



No. 3, Sec. 1, Tanxing Rd., Tanzi
Dist., Taichung City 427003 ,
Taiwan (R.O.C.)



+886-4-25381220



<https://www.adimmune.com.tw/en>

TWSE: 4142